IFF Launches POWERFRESH® ACE 2000, a Bread Fresh-Keeping Solution That 'Aces' the Shelf-Life Test
New enzyme solution delivers longer-lasting softness, operational efficiency and market-driven innovation tailored to U.S. bakery needs
Article content
NEW YORK — IFF (NYSE: IFF) — a global leader in flavors, fragrances, food ingredients, health and biosciences — announces the launch of POWERFRESH® ACE 2000 to the U.S. market. This next-generation fresh-keeping enzyme solution is designed to help industrial bakeries deliver bread with improved softness, resilience and cohesiveness throughout shelf life — meeting specific consumer demands while improving operational efficiency.
Article content
Article content
'Developed by IFF's biosciences experts, this advancement underscores our commitment to helping bakeries deliver exceptional value and maintain a competitive edge in the industry,' said Clementina Dellomonaco, senior vice president of food biosciences at IFF. 'Whenever we enhance the consumer experience, we help our customers build stronger brand equity, drive repeat purchases and unlock long-term growth.'
As ingredient prices rise and consumer expectations for long-lasting freshness continue to grow, U.S. bakeries face unprecedented pressure to maintain product quality without increasing operational strain. A recent survey shows that 60% of U.S. consumers would buy bread marketed as 'fresher for longer,' and more than half expect at least four days of freshness at purchase. 1 POWERFRESH® ACE 2000 addresses these priorities by improving softness and resilience for up to 34 days, while reducing waste and inventory complexity.
Article content
In IFF-led trials, POWERFRESH® ACE 2000 demonstrated a strong performance across both white and whole-wheat bread applications. This enzyme consistently delivered superior resilience while maintaining structure and visual appeal, even at lower dosage levels compared to market alternatives, resulting in stable loaves with excellent texture and mouthfeel. Crucially, it preserved the soft, yet easy-to-butter texture that consumers prefer, even several days after purchase.
Article content
'As a staple food, bread is a regular fixture in consumers' baskets — so expectations for quality are high and constant,' said Emily Wagener, industry leader for food and beverage enzymes for North America at IFF. 'At the same time, bakeries face challenges that require smarter solutions. POWERFRESH® ACE 2000 is bakers' ally to deliver high-quality products with the delicious texture and freshness consumers expect, every time.'
Article content
As the latest addition to IFF's established POWERFRESH® portfolio, this new solution offers a smarter path to consistent bread quality and efficiency — whether used in new formulations or to optimize existing ones. Improved product resilience enables industrial bakeries to extend distribution and better manage shelf-life targets. These operational gains also align with sustainability goals by reducing waste, minimizing returns and optimizing resources across the supply chain.
Article content
Learn more about POWERFRESH® ACE 2000 and IFF's innovative bakery enzyme portfolio here. Welcome to IFF At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in flavors, fragrances, food ingredients, health and biosciences, we deliver groundbreaking, sustainable innovations that elevate everyday products — advancing wellness, delighting the senses and enhancing the human experience. Learn more at iff.com, LinkedIn, Instagram and Facebook.
Article content
Article content
Article content
Article content
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
25 minutes ago
- CTV News
Lilly signs US$1.3 billion deal with Superluminal to discover obesity medicines using AI
A sign for Eli Lilly & Co. stands outside their corporate headquarters in Indianapolis. (AP Photo/Darron Cummings, File) Eli Lilly has signed a deal worth US$1.3 billion with privately held Superluminal Medicines to discover and develop small-molecule drugs through AI to treat obesity and other cardiometabolic diseases. Lilly currently dominates the obesity treatment market, estimated to be worth $150 billion by the next decade, and is trying to strengthen its foothold in the space through the development of next-generation drugs, acquisitions and partnerships. The deal gives Lilly exclusive rights to develop and commercialize drug candidates discovered using Superluminal's proprietary AI-driven platform targeting G-protein-coupled receptors (GPCR) - a class of proteins that can influence physiological processes including metabolism, cell growth and immune responses - the drug developer said on Thursday. Drugmakers including Danish rival Novo Nordisk are exploring potential GPCR targets to develop oral small-molecule drugs for obesity. 'GPCRs have established themselves as very important targets in the obesity and cardiometabolic landscape, but we're at the very early stages of exploration of the target class,' Superluminal CEO Cony D'Cruz told Reuters. Novo struck a $2.2 billion deal with U.S. biotech Septerna in May to develop small-molecule therapies directed at select GPCR targets. Lilly has been capitalizing on the overwhelming popularity of the GLP-1 class of medicines, including its blockbuster drug Zepbound as well as Novo's Wegovy. It is also developing a keenly watched oral GLP-1 drug, orforglipron, which has failed to meet investor expectations. The drugmaker teamed up with Hong Kong-listed biotech Laekna last year to develop an experimental obesity drug that aims to help patients lose weight while preserving muscle. As part of the deal, Superluminal is eligible to receive upfront and milestone payments, an equity investment as well as tiered royalties on net sales, the company said. Boston-based startup Superluminal is developing a wholly owned lead candidate targeting a protein called melanocortin 4 receptor to treat certain rare, genetic forms of obesity and is expected to begin human trials by fourth quarter next year. The lead candidate is not part of the deal with Lilly. Superluminal is backed by investors including RA Capital Management, Insight Partners and NVentures, NVIDIA's venture capital arm. (Reporting by Mariam Sunny in Bengaluru; Editing by Pooja Desai)
CTV News
25 minutes ago
- CTV News
Business groups alarmed about potential Air Canada shutdown
Air Canada flight attendants hold a silent protest at Montreal-Pierre Elliott Trudeau International Airport in Montreal on Monday, Aug. 11, 2025. THE CANADIAN PRESS/Christinne Muschi TORONTO — Business groups are warning of the broader impacts a shutdown at Air Canada would bring as a Saturday work stoppage over a new contract looms. Toronto Region Board of Trade chief executive Giles Gherson says even a brief shutdown would have wide-reaching economic consequences. He says a disruptive work stoppage would come as Canada is working to reboot the economy amid mounting trade pressures, making the stakes higher than ever. The Canadian Federation of Independent Business says small businesses are deeply concerned by the prospects given the massive economic uncertainty. It says one-third of Canadian small businesses depend on the summer tourism season for their revenues and members 'cannot afford to lose a single day.' More than 10,000 flight attendants are poised to walk off the job around 1 a.m. ET on Saturday, followed by a company-imposed lockout if the two sides can't reach an eleventh-hour deal. This report by The Canadian Press was first published Aug. 15, 2025. Ian Bickis, The Canadian Press
Globe and Mail
25 minutes ago
- Globe and Mail
MGE Energy Increases Dividend for 50th Consecutive Year
The board of directors of MGE Energy, Inc. (Nasdaq: MGEE), today increased the regular quarterly dividend rate 5.6% to $0.4750 per share on the outstanding shares of the company's common stock. The dividend is payable Sept. 15, 2025, to shareholders of record Sept. 1, 2025. This raises the annualized dividend rate by 10 cents from $1.80 per share to $1.90 per share. "Today's action by our board marks a milestone that only a select number of companies have achieved of increasing the dividend for 50 consecutive years, reinforcing our commitment to consistent and sustainable dividend growth and signaling the continued strength of MGE Energy's long-term business strategy for building your community energy company for the future," said Chairman, President and CEO Jeff Keebler. "MGE Energy continues to focus on our mission to provide safe, reliable, affordable and sustainable energy and on our disciplined financial management to provide ongoing value to our customers and shareholders." MGE Energy has paid cash dividends for more than 110 years. About MGE Energy MGE Energy is a public utility holding company. Its principal subsidiary, Madison Gas and Electric (MGE), generates and distributes electricity to 167,000 customers in Dane County, Wis., and purchases and distributes natural gas to 178,000 customers in seven south-central and western Wisconsin counties. MGE's roots in the Madison area date back more than 150 years.
